HCPCS Level II · Outpatient PPS (temporary codes)
C9093Injection, ranibizumab, via sustained release intravitreal implant (susvimo), 0.1 mg
Terminated 06/30/2022
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About C9093
C9093 is an HCPCS Level II code in the C series (outpatient PPS (temporary codes)), describing injection, ranibizumab, via sustained release intravitreal implant (susvimo), 0.1 mg.
It was added to HCPCS effective 04/01/2022, and its current record took effect 07/01/2022.
It was terminated on 06/30/2022 and can't be billed for later dates of service.
Its Medicare coverage code is "D", meaning special Medicare coverage instructions apply.
Details
- Short description
- Inj., susvimo, 0.1 mg
- Date added
- 04/01/2022
- Action effective
- 07/01/2022
- Termination date
- 06/30/2022
- BETOS
- O1E
Related C90xx codes
Common questions about C9093
Is HCPCS C9093 still valid?
- No. C9093 was terminated on 06/30/2022.
Does Medicare cover C9093?
- Its coverage code is "D": special Medicare coverage instructions apply. Check the local coverage determination for your region.